KRT88P and hepatitis B virus infection: Administration of chemotherapy or immunosuppressive/biologic therapy to a subject with an inactive chronic or resolved hepatitis B virus (HBV) infection (anti-HBc+) can trigger HBV reactivation (defined as the abrupt reappearance or increase of HBV DNA in the serum of a patient with previously inactive or resolved HBV infection) [42].